Inovio Pharmaceuticals Inc (NASDAQ: INO) stock fell -2.12% on Monday to $0.42 against a previous-day closing price of $0.43. With 2.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.47 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4300 whereas the lowest price it dropped to was $0.4001. The 52-week range on INO shows that it touched its highest point at $2.37 and its lowest point at $0.32 during that stretch. It currently has a 1-year price target of $0.40. Beta for the stock currently stands at 1.03.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INO was up-trending over the past week, with a rise of 20.00%, but this was down by -10.64% over a month. Three-month performance dropped to -5.62% while six-month performance fell -37.55%. The stock lost -82.05% in the past year, while it has lost -73.08% so far this year. A look at the trailing 12-month EPS for INO yields -0.63 with Next year EPS estimates of -0.33. For the next quarter, that number is -0.11. This implies an EPS growth rate of 55.27% for this year and 36.31% for next year. EPS is expected to grow by 41.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -1.47%.
Float and Shares Shorts:
At present, 272.99 million INO shares are outstanding with a float of 268.55 million shares on hand for trading. On Oct 30, 2023, short shares totaled 24.94 million, which was 9.30% higher than short shares on Sep 28, 2023. In addition to Dr. Jacqueline E. Shea Ph.D. as the firm’s CEO, President & Director, Mr. Peter D. Kies serves as its Chief Financial Officer.
Other institutions hold 9.99% of INO, in contrast to 10.90% held by mutual funds. Shares owned by individuals account for 1.92%. As the largest shareholder in INO with 7.46% of the stake, The Vanguard Group, Inc. holds 19,983,883 shares worth 19,983,883. A second-largest stockholder of INO, BlackRock Fund Advisors, holds 5,769,046 shares, controlling over 2.15% of the firm’s shares. D. E. Shaw & Co. LP is the third largest shareholder in INO, holding 5,518,837 shares or 2.06% stake. With a 3.08% stake in INO, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 8,260,428 shares are owned by the mutual fund manager. The Vanguard Strategic Small Cap Equi, which owns about 1.51% of INO stock, is the second-largest Mutual Fund holder. It holds 4,055,808 shares valued at 1.48 million. Vanguard Extended Market Index Fu holds 1.28% of the stake in INO, owning 3,423,377 shares worth 1.25 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With INO analysts setting a high price target of $0.40 and a low target of $0.40, the average target price over the next 12 months is $0.40. Based on these targets, INO could drop -4.76% to reach the target high and fall by -4.76% to reach the target low. Reaching the average price target will result in a decline of -4.76% from current levels.
Summary of Insider Activity:
Insiders traded INO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 23 while that of sell transactions has risen to 13 over the past year. The total number of shares bought during that period was 696,584 while 241,286 shares were sold.